13312amend02.doc

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT

1. CONTRACT ID CODE

PAGE OF PAGES

2. AMENDMENT/MODIFICATION NO.

00002

3. EFFECTIVE DATE

03/31/2011

4. REQUISITION/PURCHASE REQ. NO.

5. PROJECT NO. (If applicable)

FORMTEXT

Centers for Disease Control and Prevention (PGO)

Building & Facilities Contracts Branch

2920 Brandywine Road, MS-K71

Atlanta, GA 30341-5539

Centers for Disease Control and Prevention (PGO)

Building & Facilities Contracts Branch

2920 Brandywine Road, MS-K71

Atlanta, GA 30341-5539

8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)

X

9A. AMENDMENT OF SOLICITATION NO.

2011-N-13312 9B. DATED (See Item 11) 03/23/2011

10A. MODIFICATION OF CONTRACT/ORDER NO.

10B. DATED (See Item 13)

11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods:

(a) By completing Items 8 and 15, and returning submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEGMENT

TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT

IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

12. ACCOUNTING AND APPROPRIATION DATA (If required)

N/A

13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS,

IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

A.

THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN

THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

D.

OTHER (Specify type of modification and authority)

E. IMPORTANT: Contractor is not, is required to sign this document and return copies to the issuing office.

14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

The purpose of this modification is to:

a) Provide questions and answers received during the question period;

b) The due date of proposals is extended through 2:00 p.m. EST Apri1 8, 2011.

Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

15A. NAME AND TITLE OF SIGNER (Type or print)

16A. NAME OF CONTRACTING OFFICER

Christine N Godfrey

15B. CONTRACTOR/OFFEROR

(Signature of person authorized to sign)

15C. DATE SIGNED

16B. UNITED STATES OF AMERICA

BY ___________________________________________

(Signature of Contracting Officer)

16C. DATE SIGNED

NSN 7540-01-152-8070

STANDARD FORM 30 (REV. 10-83)

PREVIOUS EDITION UNUSABLE

30-105 Prescribed by GSA

FAR (48 CFR) 53.243

Pharmaceutical Transaction Data and Data Services

Solicitation Number: 2011-N-13312

Questions and Answers:

1- Is this a new requirement?

Yes.

2- Is there is an Incumbent to this opportunity. No, this is a new requirement.

If so, could you please provide the following information:

Contractor: N/A Contract Number: N/A Award Date: N/A Expiration Date: N/A Value: N/A

3- Does the vendor have to have a GSA Schedule?

No, this opportunity is not limited to GSA or other GWAC contract holders.

4- Evaluation criteria (page 10) “Relevant or Similar Experience from at least Two Projects” - If the “Offerors” identified in this section consists of a multiple firm team, will CDC evaluate the relative experience of the combined team?

An offeror comprised of a multiple firm team should endeavor to represent the prior experience upon similar accomplished work for each team member (or firm) in the most concise and contextualized manner.

5- Can you describe the % of pharmaceutical transactions that this announcement is seeking to acquire?

Data provided needs to be well characterized in terms of venue of service and context (retail chain pharmacy, retail independent pharmacy, governmental, institutional, etc) and demonstrate representation of ~ 60% of pharmaceutical dispensing locations and ~ 60% of annual pharmaceutical transactions in the U.S. (ideally, this RFP seeks >70% representation of such transactions and coverage).

6- Is there guidance in terms of HIPAA and Public Health for data that may contain PHI / PII?

Yes. The following resources provide clarification regarding PHI / PII and the HIPAA Privacy rule in terms of Public Health Surveillance:

http://www.cdc.gov/mmwr/preview/mmwrhtml/su5201a1.htm http://www.ncbi.nlm.nih.gov/pubmed/12741579 http://www.hhs.gov/ocr/privacy/hipaa/understanding/special/publichealth/index.html 7- Can a clarification of the term “chronic disease treatment / maintenance drugs” be provided?

This broad grouping could include (but not limited to) the following drug classes for medications used in the treatment of chronic diseases such as diabetes, hypertension, hypercholesterolemia, CVD, asthma, etc.:

8- Is the acquisition open to large businesses, since the RFP lists it as "unrestricted" on p. 1, but has FAR 52.219-6 Notice of Total Small Business Set Aside checked on p. 32.? Yes, this requirement is unrestricted. Page 32 has been updated as it was selected incorrectly.

9- The amendment 01 dated March 24, 2011 served to update the title of the notice due to typographical error.

10- The due date for proposals has been extended through 2:00 p.m., EST, April 18, 2011.

ITEM 10A.